Impact of Neutrophil-to-Lymphocyte Ratio in Patients with EGFR-Mutant NSCLC Treated with Tyrosine Kinase Inhibitors

被引：0
|
作者：
Ono, T. [1 ]
Igawa, S. [1 ]
Yamada, K. [1 ]
Kameda, A. [1 ]
Oguri, A. [1 ]
Yamamoto, H. [1 ]
Manabe, H. [1 ]
Ozawa, T. [1 ]
Kusuhara, S. [1 ]
Kasajima, M. [1 ]
Kakegawa, M. [1 ]
Otani, S. [1 ]
Fukui, T. [1 ]
Sasaki, J. [1 ]
Naoki, K. [1 ]
机构：
[1] Kitasato Univ, Sch Med, Dept Resp Med, Sagamihara, Kanagawa, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
EGFR-TKIs; Neutrophil-to-lymphocyte ratio; Non small cell lung cancer;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P76.53
引用
收藏
页码：S610 / S610
页数：1
相关论文
共 50 条
  • [1] Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors
    Taihei Ono
    Satoshi Igawa
    Shintaro Kurahayashi
    Yuriko Okuma
    Ai Sugimoto
    Seiichiro Kusuhara
    Takahiro Ozawa
    Tomoya Fukui
    Jiichiro Sasaki
    Hisashi Mitsufuji
    Masanori Yokoba
    Masaru Kubota
    Masato Katagiri
    Katsuhiko Naoki
    Investigational New Drugs, 2020, 38 : 885 - 893
  • [2] Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors
    Ono, Taihei
    Igawa, Satoshi
    Kurahayashi, Shintaro
    Okuma, Yuriko
    Sugimoto, Ai
    Kusuhara, Seiichiro
    Ozawa, Takahiro
    Fukui, Tomoya
    Sasaki, Jiichiro
    Mitsufuji, Hisashi
    Yokoba, Masanori
    Kubota, Masaru
    Katagiri, Masato
    Naoki, Katsuhiko
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (03) : 885 - 893
  • [3] The Role of Neutrophil-to-Lymphocyte Ratio in Advanced EGFR-Mutant NSCLC Patients Treated with First-Line Osimertinib
    Chen, Kuan-Chih
    Huang, Yen-Hsiang
    Hsu, Kuo-Hsuan
    Tseng, Jeng-Sen
    Chang, Gee-Chen
    Yang, Tsung-Ying
    ONCOTARGETS AND THERAPY, 2023, 16 : 317 - 326
  • [4] Prediction Model for Tumor Volume Nadir in EGFR-mutant NSCLC Patients Treated With EGFR Tyrosine Kinase Inhibitors
    Nishino, Mizuki
    Lu, Junwei
    Hino, Takuya
    Vokes, Natalie I.
    Janne, Pasi A.
    Hatabu, Hiroto
    Johnson, Bruce E.
    JOURNAL OF THORACIC IMAGING, 2023, 38 (02) : 82 - 87
  • [5] Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors
    Nishino, Mizuki
    Cardarella, Stephanie
    Dahlberg, Suzanne E.
    Jackman, David M.
    Ramaiya, Nikhil H.
    Hatabu, Hiroto
    Rabin, Michael S.
    Jaenne, Pasi A.
    Johnson, Bruce E.
    LUNG CANCER, 2013, 79 (03) : 283 - 288
  • [6] Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors
    Nishino, Mizuki
    Heon, Stephanie
    Dahlberg, Suzanne Eleanor
    Jackman, David Michael
    Ramaiya, Nikhil H.
    Hatabu, Hiroto
    Rabin, Michael S.
    Janne, Pasi Antero
    Johnson, Bruce E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors
    Myall, Nathaniel J.
    Whisenant, Jennifer G.
    Neal, Joel W.
    Iams, Wade T.
    Reckamp, Karen L.
    York, Sally
    Berry, Lynne D.
    Shyr, Yu
    Horn, Leora
    Wakelee, Heather A.
    Padda, Sukhmani K.
    JTO CLINICAL AND RESEARCH REPORTS, 2025, 6 (02):
  • [8] The peripheral blood neutrophil-to-lymphocyte ratio is a prognostic predictor for survival of EGFR-mutant nonsmall cell lung cancer patients treated with EGFR-TKIs
    Zhang, Yuan
    Feng, Yang-Chun
    Zhu, Hong-Ge
    Xiong, Ting-Chuan
    Hou, Yan-Shen
    Song, Jia
    Jiang, Wei
    Zhu, Chang-Jun
    MEDICINE, 2018, 97 (30)
  • [9] The Neutrophil-to-Lymphocyte Ratio is a Prognostic Biomarker in Patients with EGFR Mutated Advanced NSCLC
    Rouhani, S.
    Yun, N.
    Bestvina, C.
    Gilmore, B.
    Ritz, E.
    Tarhoni, I.
    Batus, M.
    Borgia, J.
    Bonomi, P.
    Fidler, M. J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S599 - S600
  • [10] Pretreatment neutrophil-to-lymphocyte ratio is a predictive biomarker for EGFR TKI-treated patients with advanced EGFR-mutant Non-small cell lung cancer
    Xu, Cong
    Yao, Xiaojun
    Li, Ting
    Wang, Jue
    An, Bo
    Wang, Jing
    Sui, Xinbing
    Leung, Elaine Lai-Han
    Wu, Qibiao
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (04) : 2875 - 2883
12345